SAN FRANCISCO, CA--(Marketwired - Jul 31, 2013) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. ( NASDAQ : OHRP ) ("The Company" or "OHR") and raised its twelve month price target of from $10.50 to $14.00. Ross Silver, Principal Analyst at Vista Partners, stated, "OHR is focused on developing Squalamine Eye Drops, in a Phase 2 trial, for the treatment of the wet form of age-related macular degeneration (Wet-AMD). Therapies for Wet-AMD such as ranibizumab (Lucentis®) sold by Genentech (acquired by Roche), as well as Regeneron's aflibercept (Eylea®) intravitreal injections, have become the market leaders in treating Wet-AMD and both therapies combined garnered approximately $5B of revenues in 2012. OHR's Wet-AMD clinical candidate Squalamine eye drops would seem to present a significant advantage relative to the aforementioned therapies considering the delivery method which is self-administered eye drops. Both Lucentis® and Eylea® require an injection into the back of the eye. The Squalamine Eye Drop program has the potential to create a monumental shift in the way patients are treated for Wet-AMD." Mr. Silver concludes, "OHR recently completed an up-listing to the Nasdaq, added two prestigious Board members including Dr. Thomas Riedhammer, the former President of Global Pharmaceuticals for Bausch & Lomb and strengthened its balance sheet, which according to the Company, gives them a cash runway into 2015."
To download a FREE copy of the Ohr Pharmaceutical, Inc. research report, please visit http://www.vistapglobal.com and click the "Download" icon to gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.
Please follow us on Twitter @VistaPResearch & Facebook at Vista-Partners to receive updates, thoughts and ideas about and our coverage universe of companies and more...
Disclaimer & Disclosure:
We encourage readers to view a complete list of disclaimers and disclosures on our website www.vistapglobal.com.